Molbio Diagnostics receives Kochon Prize 2024 by Stop TB Partnership

Molbio Diagnostics, an innovative point-of-care diagnostics company, has been awarded the KOCHON Prize 2024 by the Stop TB Partnership.

This recognition honours Molbio’s work in ensuring access to the latest tools, innovations, and approaches for people affected by Tuberculosis (TB) and in advancing progress toward the UNHLM targets. With this award, Molbio becomes the first private company globally—and only the third Indian entity after the Indian Council of Medical Research (ICMR) and Dr. L.S. Chauhan—to receive this distinction.

Awarded annually by the Stop TB Partnership, the Kochon Prize recognises individuals and organisations that have made significant contributions to combating tuberculosis. Established by the Kochon Foundation in memory of its late chairman, Chong-Kun Lee, the award carries a prize of $65,000 and a medal, making it the world’s largest award specifically dedicated to TB.

“We express our sincere gratitude to the Government of India and the Indian Council of Medical Research (ICMR) for their unwavering support and for endorsing the Truenat®️ platform. We also extend our thanks to the World Health Organization and the global TB community for their trust and continued support in endorsing and adopting the platform. As a gesture of appreciation, Molbio is contributing the prize money back to the Stop TB Partnership — reaffirming our shared commitment to ensuring that communities affected by TB have a strong voice and active role in shaping and advancing TB programs worldwide", said Sriram Natarajan, Executive Director and Chief Executive Officer, Molbio Diagnostics Limited.